Recent initiatives are changing the dynamics in the Japanese pharmaceutical market. At one end of the spectrum, a trial process is rewarding innovation by exempting new drugs from biennial price cuts in return for investing in areas of unmet need, whilst other measures are speeding up drug approvals. At the other end, the need to […]
This author has not written his bio yet.
But we are proud to say that groupH contributed 40 entries already.
Entries by groupH
A new era of targeted oral therapies? Rheumatoid arthritis (RA) treatment options have expanded from conventional oral therapies like methotrexate, through the era of targeted injectable biologics and into a new dawn of targeted oral treatment. Xeljanz, Pfizer’s first-in-class JAK3 inhibitor (tofacitinib), was launched in the US in 2012 – the first oral therapy approved […]
Here at groupH, we are always looking for new ways to present information, data and concepts more cleanly and more concisely. We have found the following websites inspiring, and hope you do too: Beautiful: http://www.informationisbeautiful.net/tag/health/ Informative: (The Economist’s daily chart) http://www.economist.com/blogs/graphicdetail Scientific and Statistical: http://www.datavis.ca/gallery/bright-ideas.php Tools: http://www.idea.org/blog/2012/10/25/great-tools-for-data-visualization/
Favourable market conditions. The anti-obesity market is predicted to be worth $2.4 billion by 2021, growing 21% annually. High unmet need and advantageous epidemiological trends are key drivers. At first glance, the opportunity for new therapies seems considerable. Limited success for Pharma so far. For decades drug developers have had limited success in grabbing this […]
This Christmas, as in previous years, we have made donations to our chosen charities. We are supporting the UK charity Action MS. Action MS maintains a highly successful fund-raising programme that supports research into multiple sclerosis, and an extensive range of care and support services to people and families living with MS. In addition, this […]
Each year, at Christmas time, we donate a proportion of our operating profit to our two chosen charities. The decision to support charities was taken at the very outset of the formation of groupH. It’s simply something that we feel is the right thing to do, not just something to put in our Corporate Social […]
We were very privileged to speak to Eugene Tierney, formerly head of CNS at Roche, in September 2012 at Somerset House in central London. Somerset House seemed to be a more than fitting location for this conversation – a neo-classical building dating back to the 15th century, it sits between the Strand and the River […]
You can click here for our White Paper.